Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Gw-274150. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 known ✓ | P35228 | 3/20 | 0.54 |
| ▸ | BHMT | Q93088 | 11/20 | 0.54 |
| ▸ | BHMT2 | Q9H2M3 | 1/20 | 0.54 |
| ▸ | NOS3 | P29474 | 2/20 | 0.54 |
| ▸ | NOS1 | P29475 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw-274150 SCHEMBL1690580 | 1.00 | BHMT (0.54) | BHMTBHMT2NOS2NOS3NOS1 | |
| Gw-274150 SCHEMBL120693 | 1.00 | BHMT (0.54) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL28352319 | 0.87 | TSHR (0.62) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL28352320 | 0.87 | TSHR (0.62) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL8470091 | 0.85 | ARG1 (0.53) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL5511756 | 0.85 | ARG1 (0.53) | BHMTBHMT2NOS2NOS3NOS1 | |
| SCHEMBL2757814 | 0.85 | ARG1 (0.53) | BHMTBHMT2NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL5514291 | 0.84 | ARG1 (0.51) | BHMTBHMT2NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL5514288 | 0.84 | ARG1 (0.51) | BHMTBHMT2NOS2NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL8469599 | 0.84 | ARG1 (0.51) | BHMTBHMT2NOS2NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 568 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060123-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2021-03-04 | — | — | US | claimed |
| US-20180161392-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2018-06-14 | — | — | US | claimed |
| EP-2825208-B1 | P75NTR NEUROTROPHIN BINDING PROTEIN FOR THERAPEUTIC USE | LEVICEPT LTD (GB) | 2017-05-17 | — | — | EP | claimed |
| US-20150037335-A1 | THERAPEUTIC USE OF P75NTR NEUROTROPHIN BINDING PROTEIN | LEVICEPT LTD (GB) | 2015-02-05 | — | — | US | claimed |
| EP-2175728-B1 | SODIUM CHANNEL INHIBITORS | ICAGEN INC (US) | 2014-09-10 | — | — | EP | claimed |
| US-20090111837-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PFIZER INC. | 2009-04-30 | — | — | US | claimed |
| US-20050054726-A1 | Vaccine | GLAXO GROUP LIMITED (GB) | 2005-03-10 | — | — | US | claimed |
| US-20260146036-A1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC. (JP) | 2026-05-28 | — | — | US | disclosed |
| US-20260139031-A1 | FUSION PROTEIN | LEVICEPT LTD (GB) | 2026-05-21 | — | — | US | disclosed |
| EP-4377309-B1 | CRYSTALLINE FORMS | RAQUALIA PHARMA INC (JP) | 2026-05-20 | — | — | EP | disclosed |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SEVENLESS THERAPEUTICS LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-4714435-A2 | SOLID DOSAGE FORMS AND DOSING REGIMENS COMPRISING (2R,3S,4S,5R)-4-[[3-(3,4-DIFLUORO-2-METHOXY-PHENYL)-4,5-DIMETHYL-5-(TRIFLUOROMETHYL) TETRAHYDROFURAN-2-CARBONYL]AMINO]PYRIDINE-2-CARBOXAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4712967-A2 | G-PROTEIN COUPLED RECEPTOR ANTAGONIST | Enveda Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | PFIZER, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006027681-A1 | COMBINATION OF A 5-HT(1) RECEPTOR AGONIST AND AN ALPHA-2-DELTA LIGAND FOR THE TREATMENT OF MIGRAINE | PFIZER LIMITED (GB) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006016262-A1 | COMBINATION OF A SELECTIVE NORADRENALINE REUPTAKE INHIBITOR AND A PDEV INHIBITOR | PFIZER LIMITED (GB) | 2006-02-16 | — | — | WO | disclosed |
| WO-2006011050-A2 | PYRIDINE DERIVATIVES | PFIZER LIMITED (GB) | 2006-02-02 | — | — | WO | disclosed |
| US-20050054726-A1 | Vaccine | GLAXO GROUP LIMITED (GB) | 2005-03-10 | — | — | US | disclosed |
| EP-1432440-A2 | ADJUVANTS FOR NUCLEIC ACID VACCINES | GLAXO GROUP LIMITED (GB) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003030935-A2 | ADJUVANTS FOR NUCLEIC ACID VACCINES | GLAXO GROUP LIMITED (GB) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146036-A1 | CRYSTALLINE FORMS | PRKCD, CCT8, CRYZ | NOS2 2684/4885BHMT 2204/4885BHMT2 1696/4885 |
| US-20060100460-A1 | Substituted N-sulfonylaminobenzyl-2-phenoxyacetamide compounds as VR1 receptor agonists | CNR1, AVPR1A, OPRL1 | NOS2 4367/4885BHMT 4660/4885BHMT2 4821/4885 |
| US-20260115194-A1 | NEW TREATMENTS FOR PAIN | SOS1, OPRL1, SOS2 | NOS2 4232/4885BHMT 3706/4885BHMT2 4089/4885 |
| US-20050054726-A1 | Vaccine | NOS2, NOS1, NOS3 | NOS2 1/4885BHMT 278/4885BHMT2 376/4885 |
| US-20090111837-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF NEUROPATHIC PAIN | PDE7A, PDE7B, PDE3A | NOS2 508/4885BHMT 2601/4885BHMT2 4077/4885 |
| US-20260139031-A1 | FUSION PROTEIN | NTRK2, BDNF, NGFR | NOS2 543/4885BHMT 4477/4885BHMT2 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.